前沿速览036期| CAR-T治B淋 前沿览新知
01
异体CAR-T细胞产品Cemacabtagene Ansegedleucel/ALLO-501治疗复发/难治性大B细胞淋巴瘤：ALPHA2/ALPHA I期临床研究
Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies
第一作者：Locke FL
J Clin Oncol (IF=42.1). 2025 Feb 13:101200JCO2401933.
全文网址：https://ascopubs.org/doi/10.1200/JCO-24-01933
02
循环肿瘤DNA可用于测量侵袭性B细胞淋巴瘤中残留病灶：一项叙述性综述
Circulating Tumor DNA as Measurable Residual Disease in Aggressive B-Cell Lymphoma: A Narrative Review
第一作者：Roschewski M
JAMA Oncol (IF=22.3). 2025 Feb 6.
全文网址：https://jamanetwork.com/journals/jamaoncology/article-abstract/2829928
03
Axicabtagene Ciloleucel治疗一线高危大B细胞淋巴瘤（ZUMA-12研究）的三年随访分析
Three-year follow-up analysis of first-line axicabtagene ciloleucel in high-risk large B-cell lymphoma (ZUMA-12)
第一作者：Chavez JC
Blood (IF=21.1). 2025 Feb 12:blood.2024027347.
全文网址：https://ashpublications.org/blood/article/doi/10.1182/blood.2024027347/535581/Three-year-follow-up-analysis-of-first-line
04
CAR-T细胞治疗伯基特淋巴瘤成年患者的临床结局
Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma
第一作者：Samples L
Blood (IF=21.1). 2025 Feb 12:blood.2024026831.
全文网址：https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2024026831/535580/Outcomes-Among-Adult-Recipients-of-CAR-T-cell?redirectedFrom=fulltext
05
T细胞/组织细胞丰富的大B细胞淋巴瘤患者接受CAR-T细胞治疗的效果及疾病进展后的治疗策略：GELTAMO/GETH研究
Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study
第一作者：Bastos-Oreiro M
Hemasphere (IF=11.9). 2025 Feb 4;9(2):e70077.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC11792173/
06
Brexucabtagene Autoleucel与异体造血干细胞移植治疗复发/难治性套细胞淋巴瘤的临床结局比较
Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma
第一作者：Liebers N
Blood Cancer Discov (IF=11.7). 2025 Feb 6.
全文网址：https://aacrjournals.org/bloodcancerdiscov/article-abstract/doi/10.1158/2643-3230.BCD-24-0178/751663/Brexucabtagene-autoleucel-versus-allogeneic?redirectedFrom=fulltext
07
Tisagenlecleucel治疗侵袭性B细胞淋巴瘤的真实世界结局：来自CIBMTR登记研究的亚组分析
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry
第一作者：Landsburg DJ
J Immunother Cancer (IF=10.3). 2025 Feb 9;13(2):e009890.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC11808862/
08
淋巴瘤患者在Axicabtagene Ciloleucel治疗后预防性使用阿那白滞素，其毒性相关的单细胞动态变化
Single-cell dynamics of breakthrough toxicities following anakinra prophylaxis for axicabtagene ciloleucel in lymphoma
第一作者：Frigault MJ
Blood Adv (IF=7.4). 2025 Feb 10:bloodadvances.2024015161.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024015161/535555/Single-cell-dynamics-of-breakthrough-toxicities
09
Gp350 CAR-T细胞治疗EB病毒阳性的伯基特淋巴瘤：Gp350 CAR-T的临床前研究
Gp350-targeted CAR-T therapy in EBV-positive Burkitt lymphoma: pre-clinical development of gp350 CAR-T
第一作者：Wang J
J Transl Med (IF=6.1). 2025 Feb 10;23(1):171.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC11809011/
10
在大B细胞淋巴瘤中，早期与晚期使用CAR-T细胞疗法的治疗失败模式的比较
Treatment failure patterns in early versus late introduction of CAR T-cell therapy in large B-cell lymphoma
第一作者：Corona M
Bone Marrow Transplant (IF=4.5). 2025 Feb 1.
全文网址：https://www.nature.com/articles/s41409-025-02519-z
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2025.2-17 valid until 2027.2
供稿与审核：临床开发与医学部